European ScreeningPort receives funding for IMI Call4
European ScreeningPort is partner of an international consortium that has received confirmation of an over 20 million EURO grant award from the Innovative Medicine Initiative Joint Undertaking (IMI-JU). The programme “kinetics for drug discovery – K4DD” involves 20 partners and is coordinated by Bayer Healthcare and the University of Leiden. The consortium will analyse molecular aspects of drug binding kinetics with the aim to reduce high attrition rates in drug discovery and development.
There is mounting evidence that the often ignored kinetic aspects of the interactions between a drug ligand and its target are highly relevant for clinical success. Lack of information of key kinetic parameters may be one of the reasons for the unacceptable attrition rates in drug discovery. K4DD aims at converting knowledge of binding kinetics into data-driven guidelines and easily accessible assay tools and technologies for future drug discovery. European ScreeningPort is working across all three scientific workpackages of the project, that aim to i) increase the molecular understanding of drug target interactions, ii) develop novel assays and technologies for screening approaches and iii) to develop predictive modeling approaches for the translation of the gained knowledge into In vivo models.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
